Our View of the Sector
An Industry in Motion
Dramatic increase in the complexity of medicines and new therapies
Rapidly growing portfolio of new products
A wider range of new therapies and medicines created on the dynamic biotechnology sector
Significant rise in Research and Development costs
Tighter legal restrictions on product quality
Increasingly competitive environment for pharmaceutical companies, affecting prices and profit margins (generic drugs, cutbacks on reimbursement of medicines by French Social Security, rival therapies, etc.)
Transforming the business model
The pharmaceutical industry is currently in a phase of adaptation: faced with new challenges, companies are reengineering their businesses in order to preserve profit margins and growth, thereby enabling them to develop new treatments. The major changes they need to make include :
increasing the new product launch success rate by improving R&D performance and streamlining the decision-making process for product development;
reducing the development-to-production cycle;
strengthening processes and information systems enabling them to control product quality and standards.
